Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 1,659 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Growth Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Growth Hormone and Chromosome 18q- and Abnormal Growth

NCT00134420
View directory record Official record
Conditions
Loss of Chromosome 18q, Growth Hormone Deficiency
Interventions
Nutropin AQ, Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, Neuropsychological Testing
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 30, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

NCT04423718
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Drug
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
1,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
57
States / cities
Phoenix, Arizona • Fullerton, California • Mountain View, California + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 30, 2026, 4:54 AM EDT
Recruiting Not applicable Interventional

Flow and Grow - The Ideal Time to Wean CPAP Off In Extremely Low Birth Weight Infants

NCT06123143
View directory record Official record
Conditions
Neonatal Respiratory Failure
Interventions
Standardized/structured CPAP weaning protocol
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 30 Weeks
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Escondido, California • La Jolla, California • Murrieta, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 30, 2026, 4:54 AM EDT
Completed No phase listed Observational

Transphyseal Vs. Physeal Sparing ACL Reconstruction in Skeletally Immature Patients: Risk of Subsequent Lower Extremity Growth Deformity

NCT03081026
View directory record Official record
Conditions
ACL Reconstruction
Interventions
Bilateral hip to ankle x-ray, exam and strength testing.
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
6 Years to 16 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 30, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

NCT03517449
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
827 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
25
States / cities
Phoenix, Arizona • San Francisco, California • Santa Monica, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 30, 2026, 4:54 AM EDT
Completed Phase 1 Interventional

Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2

NCT00400374
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Erlotinib, Celecoxib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Oct 30, 2026, 4:54 AM EDT
Completed Early Phase 1 Interventional Results available

A Microdose Evaluation Study of ABY-029 in Recurrent Glioma

NCT02901925
View directory record Official record
Conditions
Glioma
Interventions
ABY-029
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 30, 2026, 4:54 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Transplacental Gradients and Transport in Intrauterine Growth Restricted (IUGR) Pregnancies Compared to Normal Pregnancies.

NCT02397291
View directory record Official record
Conditions
IUGR, Pregnancy
Interventions
Mannose, Myoinositol, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 30, 2026, 4:54 AM EDT
Completed Phase 2 Interventional

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

NCT01221077
View directory record Official record
Conditions
NSCLC, Non Small Cell Lung Cancer
Interventions
OSI-906, Erlotinib, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
La Jolla, California • Tampa, Florida • Weston, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 30, 2026, 4:54 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Early DHA/ARA Supplementation in Growth-restricted Very Preterm Infants: A Randomized Clinical Trial

NCT06207071
View directory record Official record
Conditions
Infant Malnutrition, Light-For-Dates With Signs of Fetal Malnutrition, Premature, Nutrition Disorder, Infant
Interventions
DHA
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
24 Hours to 72 Hours
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 4:54 AM EDT
Withdrawn Not applicable Interventional

Assisted Exercise in Prematurity; Effects and Mechanisms

NCT00580099
View directory record Official record
Conditions
Growth, Development
Interventions
assisted exercise, cuddle
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
30 Weeks to 35 Weeks
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 30, 2026, 4:54 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT03909334
View directory record Official record
Conditions
Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer
Interventions
Osimertinib, Ramucirumab
Drug
Lead sponsor
Xiuning Le
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 30, 2026, 4:54 AM EDT
Completed Not applicable Interventional

Does Protein Restriction Inhibit Prostrate Cancer Growth

NCT01692587
View directory record Official record
Conditions
Prostate Cancer
Interventions
Protein restrictive diet
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 30, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients

NCT00082628
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Placebo, Serostim® 4 mg, Serostim® 2 mg
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 30, 2026, 4:54 AM EDT
Not yet recruiting Phase 2 Interventional

Labyrinthin Vaccination in Veterans With Lung Adenocarcinoma

NCT07859592
View directory record Official record
Conditions
Type and Grade of Toxicities, Demographic and Background Characteristics, Advanced, Metastatic, Recurrent Adenocarcinoma and Malignant Solid Neoplasm
Interventions
LabVax 3(22)-23 and GM-CSF (adjuvant) in combination with pembrolizumab
Combination Product
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
4
States / cities
Long Beach, California • Sacramento, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 30, 2026, 4:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children.

NCT00235599
View directory record Official record
Conditions
Short Stature, Growth Hormone Deficiency
Interventions
IGFBP-3 Stimulation Test
Procedure
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
4 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2007 · Synced Oct 30, 2026, 4:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fetal 3D Study (Fetal Body Composition and Volumes Study)

NCT03266198
View directory record Official record
Conditions
Fetal Growth Restriction, Fetal Growth Abnormality
Interventions
No intervention
Other
Lead sponsor
Katherine Grantz
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
2,809 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 30, 2026, 4:54 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A 6-month, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of USPlus DERM to Promote Hair Growth in Men and Women With Self-perceived Thinning Hair.

NCT06920758
View directory record Official record
Conditions
Thinning Hair
Interventions
USPlus DERM Bioactive Fatty Acids 160 mg Softgels, Placebo softgel
Dietary Supplement · Other
Lead sponsor
Ablon Skin Institute Research Center
Other
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 30, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Growth Hormone Therapy in Osteogenesis Imperfecta

NCT00001305
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Humatrope
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Years to 16 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 30, 2026, 4:54 AM EDT
Completed Phase 2 Interventional

Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism

NCT00193661
View directory record Official record
Conditions
Primary or Secondary Hypogonadism, Constitutional Delay in Growth and Puberty (CDGP)
Interventions
Testosterone Gel (1%)
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
13 Years to 17 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 30, 2026, 4:54 AM EDT
Suspended Phase 4 Interventional

Effect of Cytokines on Growth of Children With Chronic Kidney Failure

NCT00194883
View directory record Official record
Conditions
Chronic Renal Insufficiency
Interventions
Recombinant Human Growth Hormone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
6 Months to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 30, 2026, 4:54 AM EDT
Active, not recruiting Phase 3 Interventional

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

NCT05338970
View directory record Official record
Conditions
Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
Interventions
Patritumab Deruxtecan, Platinum-based chemotherapy
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
23
States / cities
Anchorage, Alaska • Springdale, Arkansas • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 30, 2026, 4:54 AM EDT
Recruiting Phase 3 Interventional

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

NCT07541079
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Giredestrant
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
8
States / cities
Fountain Valley, California • Stockton, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 4:54 AM EDT
Recruiting Not applicable Interventional

Leveraging Interventions for Caregiver Growth, Health, Training, Empowerment and Navigation: Comparing Group Behavioral Interventions to Improve Dementia Caregiver Strain

NCT07868588
View directory record Official record
Conditions
Elevated Caregiver Strain, Dementia Caregiver, Caregiver Stress
Interventions
Caring Together, Savvy Caregiver
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 4:54 AM EDT